Once weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double blind, placebo controlled and active controlled, dose finding phase 2 trial ScienceDirect Cagrilintide (AM833) Long acting amylin analog. Beta cells make TWO hormones: insulin and amylin. Amylin slows stomach emptying and reduces appetite. Cagrilintide is a long acting synthetic amylin designed for once weekly dosing Novo Nordisk's New WeightLoss Drug Just Failed a Big TrialSo Why Is It Still Headed to Market? Novo Nordisk's next generation weight loss drug CagriSema matches Lilly's Zepbound in major trial, but doesn't surpass it CNN Novo Nordisk shares slide despite promising weight loss trial results Sharecast.com Novo Nordisk's next generation weight loss drug CagriSema matches Lilly's Zepbound in major trial, but doesn't surpass it CNN